Kamada (KMDA) Raised to “B” at TheStreet
Kamada (NASDAQ:KMDA) was upgraded by analysts at TheStreet from a “c” rating to a “b” rating in a note issued to investors on Friday.
A number of other analysts also recently commented on KMDA. Zacks Investment Research upgraded Kamada from a “sell” rating to a “hold” rating in a research report on Friday. ValuEngine downgraded Kamada from a “hold” rating to a “sell” rating in a research report on Friday, February 2nd. HC Wainwright reiterated a “buy” rating on shares of Kamada in a research report on Thursday, February 8th. Chardan Capital assumed coverage on Kamada in a research report on Friday, February 2nd. They issued a “buy” rating and a $7.00 price objective for the company. Finally, Jefferies Group reiterated a “buy” rating and issued a $7.00 price objective on shares of Kamada in a research report on Thursday, October 12th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $7.00.
Shares of Kamada (KMDA) opened at $5.00 on Friday. Kamada has a 52 week low of $3.75 and a 52 week high of $8.61. The firm has a market capitalization of $201.31, a P/E ratio of 29.41 and a beta of 1.14. The company has a debt-to-equity ratio of 0.02, a quick ratio of 2.58 and a current ratio of 3.30.
Several hedge funds have recently made changes to their positions in the business. Paulson & CO. Inc. lifted its position in shares of Kamada by 8.2% in the 2nd quarter. Paulson & CO. Inc. now owns 790,800 shares of the biotechnology company’s stock worth $4,745,000 after acquiring an additional 60,000 shares during the period. Vanguard Group Inc. lifted its position in shares of Kamada by 6.5% in the 2nd quarter. Vanguard Group Inc. now owns 468,390 shares of the biotechnology company’s stock worth $2,810,000 after acquiring an additional 28,382 shares during the period. Analyst IMS Investment Management Services Ltd. lifted its position in shares of Kamada by 125.5% in the 3rd quarter. Analyst IMS Investment Management Services Ltd. now owns 89,843 shares of the biotechnology company’s stock worth $431,000 after acquiring an additional 50,000 shares during the period. ARK Investment Management LLC bought a new stake in shares of Kamada in the 4th quarter worth approximately $251,000. Finally, Worth Venture Partners LLC bought a new stake in shares of Kamada in the 3rd quarter worth approximately $246,000. Institutional investors own 6.26% of the company’s stock.
Kamada Company Profile
Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.
Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.